Clinical trials: Early-Stage Cancer
Degenerative Disc Disease
Intradiscal rhGDF-5 Phase I/II Clinical Trial
Study to show the effectiveness and safety of a single injection of rhGDF5 into a degenerating single spinal disc in treating lumbar level degenerative disc disease
- Trial name
- NCT00813813
- Testing
- Intradiscal rhGDF-5
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- DePuy Spine
Locally Advanced Breast Cancer
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
Primary Objective: Determination of pathologic complete response (pCR) rates Secondary Objective: Determination of cardiac toxicity as measured by: composite of LVEF, longitudinal strain and troponin.
- Trial name
- NCT03329378
- Testing
- Docetaxel, Carboplatin, Trastuzumab
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Relapsed or Refractory Multiple Myeloma
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone
- Trial name
- SELECT (NCT04191616)
- Testing
- Carfilzomib, Dexamethasone, Pomalidomide
- Where
- 46 sites in United States, Denmark and 6 more
- Volunteers
- 54 people
- Sponsor
- Amgen
Multiple Myeloma and Plasma Cell Neoplasm
Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma
RATIONALE: Zoledronate may prevent bone loss and stop the growth of cancer cells in bone. Thalidomide may stop the growth of cancer cells by blocking blood flow to the cancer.
- Trial name
- NCT00432458
- Testing
- Thalidomide, zoledronic acid
- Where
- 4 sites in United States
- Volunteers
- 68 people
- Sponsor
- Mayo Clinic
DCIS
Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
Breast cancer is one of the most common cancers seriously afflicting women in the United States. Of the one million incident cases that are reported annually there are approximately 193,000 new cases of breast cancer (Greenlee…
- Trial name
- NCT00256217
- Testing
- Anastrozole
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Rita Sanghvi, Mehta
Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7
O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma
This phase I/II trial studies the side effects and best dose of carmustine when given together with O6-benzylguanine and to see how well they work in treating patients with stage IA-IIA cutaneous T-cell lymphoma.
- Conditions
- Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7
- Trial name
- NCT00961220
- Testing
- Carmustine, Laboratory Biomarker Analysis, O6-Benzylguanine
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00066222
- Testing
- Cisplatin, Etoposide, Radiation therapy
- Where
- 104 sites in United States
- Volunteers
- 72 people
- Sponsor
- Radiation Therapy Oncology Group
Non-Small Cell Lung Cancer
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer
Rationale: Vaccines made from allogeneic tumor cells may help the body build an effective immune response to kill tumor cells. The Purpose of this study is to evaluate the effects of a lung cancer vaccine in patients with Stage I…
- Trial name
- NCT00654030
- Testing
- 1650-G Vaccine
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Edward Hirschowitz
Chronic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease
Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
The purpose of the study is to determine whether tolvaptan is effective and safe for the treatment of late-stage chronic kidney disease due to autosomal dominant polycystic kidney disease (ADPKD)
- Trial name
- NCT02160145
- Testing
- Tolvaptan (OPC-41061)
- Where
- 230 sites in United States, Argentina and 20 more
- Volunteers
- 1,370 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Breast Cancer, Fatigue
Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02
RATIONALE: Learning about the long-term effects of adjuvant tamoxifen (T), adjuvant tamoxifen with ovarian function suppression (T+OFS), and exemestane with ovarian function suppression (E+ OFS) on brain function may help doctors…
- Conditions
- Breast Cancer, Fatigue, Sleep Disorders
- Trial name
- Co-SOFT (NCT00659373)
- Testing
- Tamoxifen, triptorelin, Exemestane
- Where
- 15 sites in United States, Canada
- Volunteers
- 86 people
- Sponsor
- ETOP IBCSG Partners Foundation
Estrogen Receptor Positive, HER2/Neu Negative
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
This clinical trial studies fluorine F 18 fluorothymidine (FLT) positron emission tomography (PET) in measuring treatment response in patients with newly diagnosed estrogen receptor (ER)-positive, human epidermal growth factor…
- Conditions
- Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Stage IA Breast Cancer
- Trial name
- NCT01928186
- Testing
- Fluorothymidine F-18, Positron Emission Tomography, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Washington
Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma
Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer
This early-phase trial tests the safety and side effects of a tolinapant given together with radiation therapy in treating patients with head and neck cancer for which the patient has not received treatment in the past…
- Conditions
- Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT05245682
- Testing
- Tolinapant, Radiation Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Emory University
Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
This phase III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer.
- Conditions
- Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
- Trial name
- NCT03811002
- Testing
- 3-Dimensional Conformal Radiation Therapy, Atezolizumab, Biospecimen Collection
- Where
- 542 sites in United States, Japan
- Volunteers
- 544 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer
This is a non-randomized, Phase II study. Efficacy is not a primary endpoint in this study; however, progression-free survival will be followed and determined for the patients in this study.
- Trial name
- NCT00629499
- Testing
- nab paclitaxel, Cyclophosphamide, Trastuzumab
- Where
- 10 sites in United States
- Volunteers
- 63 people
- Sponsor
- SCRI Development Innovations, LLC
Early Stage Lung Cancer (I and II)
Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer
Lung cancer is the leading cause of cancer death in the country, surpassing deaths caused by colorectal, prostate and breast cancers combined.
- Trial name
- NCT04515004
- Testing
- leucoselect phytosome
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- VA Office of Research and Development
Male Breast Cancer, Nausea and Vomiting
Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer
RATIONALE: Antiemetic drugs, such as dexamethasone, ondansetron hydrochloride, and palonosetron hydrochloride, may help lessen or prevent nausea and vomiting caused by chemotherapy.
- Conditions
- Male Breast Cancer, Nausea and Vomiting, Stage I Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT00343863
- Testing
- palonosetron hydrochloride, cyclophosphamide, dexamethasone
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Washington
Glioblastoma, Recurrent Glioblastoma
VB-111 in Surgically Accessible Recurrent/Progressive GBM
This research study is studying a new viral cancer therapy, ofranergene obadenovec (VB-111), for recurrent or progressive glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment.
- Trial name
- NCT04406272
- Testing
- VB11, Surgery, Bevacizumab
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Dana-Farber Cancer Institute
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer
This phase II trial studies how well rifaximin works for the treatment of gastrointestinal toxicities related to pertuzumab-based therapy in patients with stage I-III HER2 positive breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04249622
- Testing
- Best Practice, Questionnaire Administration, Rifaximin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Hidradenitis Suppurativa
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
Investigators hypothesize that ruxolitinib 1.5% cream is an effective therapy for HS participants through inhibition of inflammatory activity.
- Trial name
- NCT04414514
- Testing
- Ruxolitinib 1.5% Cream
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Milton S. Hershey Medical Center
Covid19
Treatment of Covid-19 With a Herbal Compound, Xagrotin
This is an interventional, multi-center, randomized study. Adults with confirmed covid-19 disease not more than 10 days before enrollment date were recruited (n=361).
- Trial name
- NCT05017493
- Testing
- Xagrotin
- Where
- Iraq
- Volunteers
- 661 people
- Sponsor
- Biomad AS